Idioma:

Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer

Risom, Tyler ; Langer, Ellen M ; Chapman, Margaret P ; Rantala, Juha ; Fields, Andrew J ; Boniface, Christopher ; Alvarez, Mariano J ; Kendsersky, Nicholas D ; Pelz, Carl R ; Johnson-Camacho, Katherine ; Dobrolecki, Lacey E ; Chin, Koei ; Aswani, Anil J ; Wang, Nicholas J ; Califano, Andrea ; Lewis, Michael T ; Tomlin, Claire J ; Spellman, Paul T ; Adey, Andrew ; Gray, Joe W ; Sears, Rosalie C

Nature communications, 2018-09, Vol.9 (1), p.3815-17, Article 3815 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
Autor: Risom, Tyler ; Langer, Ellen M ; Chapman, Margaret P ; Rantala, Juha ; Fields, Andrew J ; Boniface, Christopher ; Alvarez, Mariano J ; Kendsersky, Nicholas D ; Pelz, Carl R ; Johnson-Camacho, Katherine ; Dobrolecki, Lacey E ; Chin, Koei ; Aswani, Anil J ; Wang, Nicholas J ; Califano, Andrea ; Lewis, Michael T ; Tomlin, Claire J ; Spellman, Paul T ; Adey, Andrew ; Gray, Joe W ; Sears, Rosalie C
Assuntos: 1-Phosphatidylinositol 3-kinase ; Animals ; Antineoplastic Agents - therapeutic use ; Architecture ; Azepines - pharmacology ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Cancer ; Cell death ; Cell Differentiation ; Cell Line, Tumor ; Cell Plasticity ; Chemical compounds ; Chromatin - metabolism ; Chromatin remodeling ; Cytotoxicity ; Differentiation ; Drug Resistance, Neoplasm ; Female ; Genomic instability ; Heterogeneity ; Humans ; Inhibitors ; Mice, Inbred NOD ; Mice, SCID ; Molecular Targeted Therapy ; Pharmacology ; Plastic properties ; Plasticity ; Robustness (mathematics) ; Stability ; Subpopulations ; TOR protein ; Triazoles - pharmacology ; Triple Negative Breast Neoplasms - pathology ; Xenografts ; Xenotransplantation
É parte de: Nature communications, 2018-09, Vol.9 (1), p.3815-17, Article 3815
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Intratumoral heterogeneity in cancers arises from genomic instability and epigenomic plasticity and is associated with resistance to cytotoxic and targeted therapies. We show here that cell-state heterogeneity, defined by differentiation-state marker expression, is high in triple-negative and basal-like breast cancer subtypes, and that drug tolerant persister (DTP) cell populations with altered marker expression emerge during treatment with a wide range of pathway-targeted therapeutic compounds. We show that MEK and PI3K/mTOR inhibitor-driven DTP states arise through distinct cell-state transitions rather than by Darwinian selection of preexisting subpopulations, and that these transitions involve dynamic remodeling of open chromatin architecture. Increased activity of many chromatin modifier enzymes, including BRD4, is observed in DTP cells. Co-treatment with the PI3K/mTOR inhibitor BEZ235 and the BET inhibitor JQ1 prevents changes to the open chromatin architecture, inhibits the acquisition of a DTP state, and results in robust cell death in vitro and xenograft regression in vivo.
Editor: England: Nature Publishing Group
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer

England: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.